Stay up-to-date with current information and resources

Register with and you'll receive valuable information and resources, as they become available, to keep you current and help ensure you can meet the treatment needs of your patients.

Register for Updates

For US Healthcare Professionals Only

Ready-to-use CARDENE® I.V. (nicardipine hydrochloride) for blood pressure reduction in neuroemergencies

Key considerations for choosing an antihypertensive agent in neuroemergencies


CARDENE® I.V. (nicardipine hydrochloride) Premixed Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits.

CARDENE I.V. is not indicated for the treatment or prevention of AIS, ICH, or SAH

CARDENE I.V. achieved rapid BP reduction in patients with AIS, ICH, or SAH, with control maintained over 24 hours3

30 Minutes* to Achieve Goal BP

Adapted from Liu-DeRyke, 2013.

A prospective, pseudo-randomized study of patients who presented to the ED with primary ICH (n=16), SAH (n=1), or AIS (n=9) receiving CARDENE I.V. for 24 hours. CARDENE I.V. was administered at 5 mg/hr and increased every 15 minutes by 2.5 mg/hr until target SBP range was reached or a maximum of 15 mg/hr was achieved. BP goals were defined using current consensus recommendations. Vital signs (BP and HR) were taken every 15 minutes until goal BP was achieved.3

Did you know?

In AIS, management of hypertension is key in the timing of fibrinolytic therapy?4

The information on this site is only intended for US Healthcare Professionals

I am a US Healthcare Professional


I am NOT a US Healthcare Professional